Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ARVN vs SLDB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SLDB Captures Overall Composite Edge (36.5 SELL vs 52.9 HOLD), While ARVN Leads 4–1 on Growth & Valuation Pillars

SLDB Overall Winner 6-Pillar Tally: ARVN 4 – 1 SLDB (1 Tie) Matrix Metrics: ARVN 6 – 4 SLDB

As of Nov 16, 2026, Solid Biosciences Inc. (SLDB) captures the overall head-to-head institutional edge over Arvinas, Inc (ARVN) on higher Unified Composite conviction (36.5/100 SELL vs. 52.9/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality), while ARVN wins 4–1 across the 6-pillar growth and valuation breakdown. ARVN trades at $6.74 (17.9x Forward P/E, -10.1% operating margin) versus SLDB at $6.57 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ARVN currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. SLDB 36.5/100 SELL), SLDB captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10.1% operating margin) and revenue trajectory (-100.0% vs. -98.8% YoY).
  • Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile SLDB is in a Breakdown options structure phase (RSI 47.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ARVN vs SLDB
ARVN NASDAQ
Arvinas, Inc
Pharmaceutical Preparations
$6.74
-1.17% 1D
Market Cap $449.9M
TTM Revenue $275M
Forward P/E 17.9x
Beta / 30D Vol 1.40β · 66% Vol
Unified Composite Score
52.9 / 100 HOLD
Tech 54.0 Fund 59.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.6%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $7.22 · SMA50: $7.57
SLDB NASDAQ Head-to-Head Winner
Solid Biosciences Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.57
-4.02% 1D
Market Cap $781.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.14β · 76% Vol
Unified Composite Score
36.5 / 100 SELL
Tech 15.0 Fund 36.0 Flow 70.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.8 · SMA20: $6.49 · SMA50: $7.12

6-Pillar Scorecard Institutional Category Breakdown (ARVN 4 – 1 SLDB)

Columns: Metric · ARVN · SLDB
1. Valuation Multiples ARVN
Forward P/E 17.9x N/M
Trailing P/E 17.9x N/M
PEG Ratio N/M N/M
EV / Revenue 1.3x N/M
2. Growth & Scale ARVN
Revenue Growth (YoY) -98.8% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $275M N/A
Market Cap $449.9M $781.3M
3. Profitability & Quality SLDB
Gross Margin 96.7% N/A
Operating Margin -10.1% 0.0%
Net Profit Margin -3.5% 0.0%
Return on Equity (ROE) -1.8% -76.9%
4. Balance Sheet & Cash Flow ARVN
Cash Generation (TTM) -$160M -$200M
Cash Flow Margin -58.0% N/A
Net Cash / Leverage $81M Net Cash $106M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ARVN
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 108.7% (25th %ile) 103.7% (15th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) 0.08x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ARVN (6) vs SLDB (4)
Institutional Metric ARVN SLDB Criterion Row Edge
Market Capitalization
Scale
$449.9M $781.3M Larger Scale SLDB
Trailing P/E Ratio
Valuation
17.9x N/M Lower Multiple ARVN
Forward P/E Ratio
Valuation
17.9x N/M Lower Multiple ARVN
Revenue Growth (YoY)
Growth
-98.8% -100.0% Higher Growth ARVN
Operating Margin (TTM)
Profitability
-10.1% 0.0% Higher Margin SLDB
Net Profit Margin
Profitability
-3.5% 0.0% Higher Margin SLDB
Return on Equity (ROE)
Capital Efficiency
-1.8% -76.9% Higher ROE ARVN
52-Week Range Position
Momentum
5% ($6–$15) 33% ($4–$11) Stronger Trend SLDB
Beta / 30D Volatility
Risk Regime
1.40β · 66% Vol 2.14β · 76% Vol Lower Realized Risk ARVN
Unified Institutional Score
Composite Signal
52.9 / 100 (HOLD) 36.5 / 100 (SELL) Higher Composite ARVN
Trailing 12M Revenue (USD)
Operating Scale
$275M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
96.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$160M ($81M Net Cash) -$200M ($106M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SLDB +22.02 pp
ARVN: -3.3% · SLDB: +18.72%
3M Horizon ARVN +0.49 pp
ARVN: -27.21% · SLDB: -27.7%
6M Horizon SLDB +24.07 pp
ARVN: -23.23% · SLDB: +0.84%
1Y Horizon SLDB +86.07 pp
ARVN: -33.4% · SLDB: +52.67%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ARVN Revenue SLDB Revenue ARVN Op. Margin SLDB Op. Margin Margin Leader
FY2018 $10M N/A -306.3% N/A ARVN
FY2019 $20M N/A -281.4% N/A ARVN
FY2020 $20M N/A -554.1% N/A ARVN
FY2021 $50M $10M -403.4% -530.5% ARVN
FY2022 $130M $10M -200.3% -1315.2% ARVN
FY2023 $80M N/A -511.5% N/A ARVN
FY2024 $260M N/A -95.0% N/A ARVN
FY2025 $260M N/A -45.1% N/A ARVN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ARVN BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 108.7%
IV Percentile 25th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ARVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SLDB BREAKDOWN
93d in phase · OBV ACCUMULATION
Current IV 103.7%
IV Percentile 15th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SLDB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ARVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $449.9M market capitalization and -10.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SLDB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $781.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ARVN vs SLDB Key Questions & Quantitative Answers

As of Nov 16, 2026, Solid Biosciences Inc. (SLDB) captures the overall head-to-head institutional edge over Arvinas, Inc (ARVN) on higher Unified Composite conviction (36.5/100 SELL vs. 52.9/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality), while ARVN wins 4–1 across the 6-pillar growth and valuation breakdown. ARVN trades at $6.74 (17.9x Forward P/E, -10.1% operating margin) versus SLDB at $6.57 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ARVN currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. SLDB 36.5/100 SELL), SLDB captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10.1% operating margin) and revenue trajectory (-100.0% vs. -98.8% YoY). Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile SLDB is in a Breakdown options structure phase (RSI 47.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ARVN leads the Growth & Scale pillar: ARVN posts -98.8% YoY revenue growth and +0.0% YoY earnings growth on $275M TTM revenue (96.7% gross margin, -10.1% operating margin), compared with SLDB at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ARVN cumulative revenue shifted +2500.0% while SLDB shifted +0.0%. In operating R&D and SG&A reinvestment, ARVN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SLDB.

ARVN screens cheaper on headline valuation multiples. ARVN trades at 17.9x Forward P/E, 17.9x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-58.0% FCF margin), whereas SLDB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARVN (-1.8% ROE) versus SLDB (-76.9% ROE) capital efficiency.

In options market volatility and institutional positioning, ARVN carries 108.7% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 66% Vol realized risk). By comparison, SLDB carries 103.7% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.14β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.